Full formMedical & Health
VDZstands forVedolizumab
Full Form of VDZ
What is VDZ?
Vedolizumab, abbreviated as VDZ, is a humanised monoclonal antibody classified as a gut-selective anti-integrin biologic therapy. It works by blocking the alpha-4 beta-7 integrin on the surface of circulating white blood cells, preventing them from binding to MAdCAM-1 molecules in the intestinal lining and thereby reducing localised inflammation in the gut. In India, VDZ is prescribed by consultant gastroenterologists for adult patients suffering from moderate to severe ulcerative colitis and Crohn's disease who have not responded adequately to conventional treatments such as corticosteroids, immunomodulators, or anti-TNF agents like infliximab and adalimumab. The drug is administered through intravenous infusion, typically at weeks zero, two, and six, followed by maintenance doses every eight weeks at specialised infusion centres across metropolitan cities like Mumbai, Delhi, Bengaluru, and Chennai. It represents a significant advance in the management of inflammatory bowel disease, offering a targeted approach with a favourable safety profile owing to its gut-specific mechanism. For medical students and postgraduate aspirants, understanding VDZ is important for exams like NEET-PG and INI-CET under pharmacology and gastroenterology topics covering biologic therapies.
VDZ का फुल फॉर्म
वेडोलिज़ुमैब
Example
Dr Sharma recommended VDZ infusion for the patient with refractory ulcerative colitis who had failed to respond adequately to two prior lines of conventional therapy.
VDZ — frequently asked questions
What is the full form of VDZ?
VDZ stands for Vedolizumab, a humanised monoclonal antibody used as a biologic therapy for inflammatory bowel diseases.
How is Vedolizumab administered to patients in India?
It is administered as an intravenous infusion at specialised centres, with induction doses at weeks 0, 2, and 6, followed by maintenance doses every 8 weeks.
Is VDZ available and approved for use in India?
Yes, Vedolizumab is available in India under the brand name Entyvio and is prescribed by gastroenterologists for moderate to severe ulcerative colitis and Crohn's disease.